De Novo Antibody Design
Acronym for: Zero-Shot Biologics Design
Also known as: GenerativeCDR Design, Computational Affinity Maturation, RFdiffusion Antibody
The computational generation of novel complementary-determining region (CDR) loops, nanobodies (VHH), or bispecific antibody scaffolds targeted to a specific 3D epitope without relying on animal immunization or phage-display library panning.
Architectural Role in Modern Life Science R&D
Traditional hybridoma immunization and phage display require 6 to 12 months and struggle to hit conserved, recessed, or conformational epitopes on GPCRs and ion channels. De novo antibody design pairs equivariant diffusion models (such as Baker Lab RFdiffusion, Chroma, and Absci zero-shot models) with inverse folding networks (ProteinMPNN) and developability filters. These pipelines simultaneously optimize nanomolar target binding affinity (KD), thermostability (Tm > 70C), low self-association viscosity, and human germline humanness to minimize clinical anti-drug antibody (ADA) immunogenicity. Why does this matter for your lab? If you're scaling De Novo Antibody Design in production, we've found you can't treat it as a black box. You'll need tight wet-lab calibration, and we always recommend validating your pipeline against orthogonal assays before you lock in your budget.
Evaluation & Wet-Lab Integration Checklist
How do you evaluate De Novo Antibody Design without wasting six months? Start small. When we audit R&D informatics teams, we tell you to test three things first: prospective wet-lab accuracy (like SPR or Cryo-EM), native API sync with your ELN, and containerized GPU costs. Don't skip the retrospective benchmark. It's the fastest way to see if a vendor's model actually works on your proprietary targets.
Context
Traditional hybridoma immunization and phage display require 6 to 12 months and struggle to hit conserved, recessed, or conformational epitopes on GPCRs and ion channels. De novo antibody design pairs equivariant diffusion models (such as Baker Lab RFdiffusion, Chroma, and Absci zero-shot models) with inverse folding networks (ProteinMPNN) and developability filters. These pipelines simultaneously optimize nanomolar target binding affinity (KD), thermostability (Tm > 70C), low self-association viscosity, and human germline humanness to minimize clinical anti-drug antibody (ADA) immunogenicity. Why does this matter for your lab? If you're scaling De Novo Antibody Design in production, we've found you can't treat it as a black box. You'll need tight wet-lab calibration, and we always recommend validating your pipeline against orthogonal assays before you lock in your budget.
Examples
- 1Absci designing zero-shot de novo antibodies against HER2 and calprotectin (ABS-101) validated by surface plasmon resonance (SPR) with sub-nanomolar affinity and entering Phase I clinical studies.
- 2Using fine-tuned RFdiffusion to generate de novo VHH nanobodies targeting influenza hemagglutinin and Clostridium difficile toxin B, confirmed by cryo-EM at 2.8 Angstrom resolution.
- 3Generate:Biomedicines applying Chroma programmable biology models to optimize anti-TSLP monoclonal antibodies with extended half-life.
Implementing Agents
AI agents that implement or utilize De Novo Antibody Design:
Absci Corporation
Combines SoluPro E. Coli high-throughput multiplex assays with zero-shot generative CDR design.
Combines SoluPro E. Coli high-throughput multiplex assays with zero-shot generative CDR design.
Generate:Biomedicines
Develops the Chroma diffusion architecture and clinical-stage de novo protein therapeutics.
Develops the Chroma diffusion architecture and clinical-stage de novo protein therapeutics.
Xaira Therapeutics
Backed by $1B+ to scale RFdiffusion and RFantibody models from the Institute for Protein Design into clinical biologics.
Backed by $1B+ to scale RFdiffusion and RFantibody models from the Institute for Protein Design into clinical biologics.
Common Industries
Related Terms
Learn More
Verified References & Citations (2)
- [1]
De novo design of high-affinity protein binders and VHH nanobodies using RFdiffusion.
- [2]
Unlocking de novo antibody design with generative AI validated via wet-lab SPR screening.
Unlocking de novo antibody design with generative AI (Absci / bioRxiv) (Cold Spring Harbor Laboratory)